Stay Updated
  1. FEIBA Prescribing Information.
  2. What is an inhibitor? National Hemophilia Foundation website. http://www.hemophilia.org/Bleeding-Disorders/Inhibitors-Other-Complications/Inhibitors-for-Consumers/What-is-an-Inhibitor. Accessed November 6, 2018.
  3. An introduction to hemophilia. In: All About Hemophilia: A Guide for Families. Montreal, Quebec, Canada: Canadian Hemophilia Society; 2010. http://www.hemophilia.ca/files/Chapter%2001.pdf. Accessed November 6, 2018.
  4. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia. 2002;8(3):280-287.
  5. The challenges of inhibitors. National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=239&contentid=418&rptname=inhibitors. Accessed November 6, 2018.
  6. Who is at risk for developing inhibitors? National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=232&contentid=411&rptname=inhibitors. Accessed November 6, 2018.
  7. Aledort LM, DiMichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4(1):68.
  8. Kempton CL. Inhibitors in previously treated patients: a review of the literature. Haemophilia. 2010;16(102):61-65.
  9. Kasper CK. Diagnosis and Management of Inhibitors for Factors VIII and IX: An Introductory Discussion for Physicians. Montreal, Quebec, Canada: World Federation of Hemophilia; 2004.
  10. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004;77(2):187-193.
  11. Peerlinck K, Jacquemin M. Characteristics of inhibitors in mild/moderate haemophilia A. Haemophilia. 2006;12(suppl 6):43-47.
  12. Soucie JM, Symons J IV, Evatt B, et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7(2):198-206.
  13. Tjønnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag. 2007;3(4):527-531.
  14. Rota M, Cortesi PA, Crea R, et al. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017;1(26):2637-2642.
  15. Data on file.
  16. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia. 2006;12(suppl 5):14-19.
  17. Data on file.
  18. MASAC recommendation regarding the use of bypassing agents in patients with hemophilia A or B and inhibitors. MASAC Recommendation #167. National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=579. Accessed November 6, 2018.
  19. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3-9.
  20. Management of bleeds. In: All About Hemophilia: A Guide for Families. Montreal, Quebec, Canada: Canadian Hemophilia Society; 2010. http://www.hemophilia.ca/files/Chapter%2004.pdf. Accessed November 6, 2018.
  21. MASAC recommendation regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors. MASAC Recommendation #220. National Hemophilia Foundation website. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Regarding-Prophylaxis-with-Bypassing-Agents-in-Patients-with-Hemophilia-and-High-Titer-Inhibitors. Accessed November 6, 2018.
  22. Medical and Scientific Advisory Council (MASAC). National Hemophilia Foundation website. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=156&contentid=335. Accessed November 6, 2018.
  23. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20(1):65-72.
  24. Do the 5! National Hemophilia Foundation Steps for Living website. http://stepsforliving.hemophilia.org/next-step/maintaining-a-healthy-body/do-the-5. Accessed November 6, 2018.
  25. Blood clots. Medical Dictionary website. http://medical-dictionary.thefreedictionary.com/Blood+Clots. Accessed November 6, 2018.
  26. Glossary. National Hemophilia Foundation website. https://www.hemophilia.org/Glossary. Accessed November 6, 2018.
Sign up

Cookie Use Notification

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies
as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies.

      Find out more

See LessMore

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EVENTS INVOLVING CLOTS THAT BLOCK BLOOD VESSELS
Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA,

What is FEIBA?

FEIBA is an Anti-Inhibitor Coagulant Complex approved for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Use around the time of surgery
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Detailed Important Risk Information

WARNING: EVENTS INVOLVING CLOTS THAT BLOCK BLOOD VESSELS

  • Blood clots that block blood vessels and their effects have been reported during post-marketing surveillance following infusion of FEIBA, particularly following administration of high doses (above 200 units per kg per day) and/or in patients at risk for forming blood clots.
  • If you experience any of these side effects, call your doctor right away.
Toggle Important Safety Information
You’re now leaving this site.

Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.

Takeda provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.

Continue Stay on Site
';